Edition:
United Kingdom

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

5.41USD
9:02pm BST
Change (% chg)

$0.20 (+3.84%)
Prev Close
$5.21
Open
$5.21
Day's High
$5.44
Day's Low
$5.21
Volume
152,026
Avg. Vol
260,067
52-wk High
$28.74
52-wk Low
$4.99

Latest Key Developments (Source: Significant Developments)

Diplomat Pharmacy Inc - Davison's Base Salary Will Be $450,000
Friday, 15 Mar 2019 

March 15 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC - DAVISON'S BASE SALARY WILL BE $450,000.DIPLOMAT PHARMACY INC - COMPANY SHALL PAY KAVTHEKAR A LUMP-SUM PAYMENT OF $112,500.  Full Article

Diplomat Pharmacy Reports Q4 Loss Per Share Of $4.00
Friday, 15 Mar 2019 

March 15 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 4TH QUARTER AND 2018 YEAR END FINANCIAL RESULTS; PROVIDES REVISED 2019 GUIDANCE.Q4 LOSS PER SHARE $4.00.Q4 REVENUE $1.361 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.41 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.23 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $4.7 BILLION TO $5.0 BILLION.SEES 2019 SPECIALTY SEGMENT REVENUE BETWEEN $4.4 AND $4.6 BILLION.SEES 2019 DILUTED LOSS PER SHARE BETWEEN $0.50 AND $0.34.SEES 2019 PBM SEGMENT REVENUE BETWEEN $0.3 AND $0.4 BILLION.MARKET CONDITIONS IN 2019 ARE SIGNIFICANTLY MORE CHALLENGING THAN EXPECTED IN SPECIALTY AND PBM BUSINESSES.DIPLOMAT PHARMACY - CO'S COST STRUCTURE NO LONGER SUPPORTED BY CURRENT BUSINESS ENVIRONMENT AND CO IS ACCELERATING OPERATIONAL EFFICIENCY INITIATIVES.DIPLOMAT - Q4 RESULTS DRIVEN BY $262 MILLION NON-CASH IMPAIRMENT CHARGE RELATED TO GOODWILL, DEFINITE-LIVED INTANGIBLE ASSETS ASSOCIATED WITH PBM UNIT.FY2019 REVENUE VIEW $5.45 BILLION -- REFINITIV IBES DATA.  Full Article

Diplomat Pharmacy Says Jeff Park Resigned From Board Of Directors
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES RESIGNATION OF JEFF PARK FROM BOARD OF DIRECTORS.DIPLOMAT PHARMACY INC - ACCEPTED RESIGNATION OF DIRECTOR JEFF PARK, EFFECTIVE FEB. 22, 2019..  Full Article

Diplomat Pharmacy Sees FY 2018 Revenue $5.5 Bln To $5.6 Bln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PROVIDES UPDATED 2018 GUIDANCE AND PRELIMINARY 2019 OUTLOOK.SEES FY 2018 GAAP LOSS PER SHARE $0.00 TO $0.08.SEES FY 2018 REVENUE $5.5 BILLION TO $5.6 BILLION.CHAIRMAN & CEO GRIFFIN TO DIRECTLY LEAD CASTIARX PENDING SEARCH FOR NEW LEADERSHIP.DIPLOMAT PRESIDENT SABAN, AND CASTIARX PRESIDENT AND COO THIGPEN TO LEAVE COMPANY EFFECTIVE IMMEDIATELY.NOW EXPECTS 2018 REVENUE TO BE AT LOWER END OF $5.5 BILLION-$5.7 BILLION RANGE.SEES 2019 REVENUE IN RANGE OF $5.6 BILLION TO $5.8 BILLION.DIPLOMAT PHARMACY SEES FLAT TO LOW-SINGLE-DIGIT PERCENT YEAR-OVER-YEAR ADJUSTED EBITDA GROWTH IN 2019 COMPARED TO MID-POINT OF UPDATED 2018 GUIDANCE.SEES PRELIMINARY 2019 OUTLOOK ASSUMES A REVENUE CONTRIBUTION FROM CASTIARX OF $450 MILLION TO $500 MILLION.FY2018 REVENUE VIEW $5.56 BILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $5.86 BILLION -- REFINITIV IBES DATA.  Full Article

Diplomat Announces Q3 Earnings Per Share $0.00
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 3RD QUARTER FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.00.Q3 REVENUE $1.373 BILLION VERSUS I/B/E/S VIEW $1.42 BILLION.SEES FY 2018 LOSS PER SHARE $0.10 TO $+0.03.SEES FY 2018 REVENUE $5.5 BILLION TO $5.7 BILLION.Q3 EARNINGS PER SHARE VIEW $0.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Diplomat Pharmacy Files For Potential Stock Shelf, Size Undisclosed
Friday, 6 Apr 2018 

April 6 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC FILES FOR POTENTIAL STOCK SHELF, SIZE NOT DISCLOSED - SEC FILING.  Full Article

Diplomat Pharmacy Posts Q4 Adj. Earnings Per Share $0.18
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 4TH QUARTER AND 2017 YEAR END FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.18.Q4 EARNINGS PER SHARE $0.09.SEES FY 2018 EARNINGS PER SHARE $0.06 TO $0.17.SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION.SEES 2018 ADJUSTED EPS BETWEEN $0.87 AND $0.97.‍REVENUE FOR Q4 OF 2017 WAS $1,155 MILLION, COMPARED TO $1,145 MILLION IN Q4 OF 2016​.FY2018 EARNINGS PER SHARE VIEW $1.02, REVENUE VIEW $5.42 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $0.16, REVENUE VIEW $1.17 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Diplomat Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC - ‍JEFF PARK, HAS BEEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY​.DIPLOMAT PHARMACY INC - PHIL HAGERMAN TO CONTINUE SERVICE ON BOARD AND BECOME CHAIRMAN EMERITUS.DIPLOMAT PHARMACY INC - BOARD HAS APPOINTED BEN WOLIN, INDEPENDENT LEAD DIRECTOR, AS CHAIRMAN OF DIPLOMAT BOARD, EFFECTIVE IMMEDIATELY.DIPLOMAT INITIATES CEO TRANSITION; REAFFIRMS 2017 GUIDANCE AND PROVIDES PRELIMINARY 2018 OUTLOOK.DIPLOMAT PHARMACY - ‍PARK'S APPOINTMENT FOLLOWS RETIREMENT OF PHIL HAGERMAN.DIPLOMAT PHARMACY INC - IN 2018, DIPLOMAT PRELIMINARILY EXPECTS REVENUE IN RANGE OF $5.3 TO $5.6 BILLION.  Full Article

Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Diplomat Pharmacy Inc ::- EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE.FY2018 EARNINGS PER SHARE VIEW $0.95, REVENUE VIEW $5.38 BILLION -- THOMSON REUTERS I/B/E/S.DIPLOMAT REAFFIRMS 2017 GUIDANCE, PROVIDES PRELIMINARY 2018 OUTLOOK.SEES FY 2018 REVENUE UP ABOUT 20 PERCENT.SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION.- IN 2018, EXPECTS ADJUSTED EBITDA IN RANGE OF $164 TO $170 MILLION.  Full Article

Diplomat Completes Acquisition Of LDI Integrated Pharmacy Services
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT COMPLETES ACQUISITION OF LDI INTEGRATED PHARMACY SERVICES, SECURES NEW CREDIT FACILITIES.DIPLOMAT PHARMACY INC - ENTERED INTO NEW $800 MILLION SENIOR SECURED CREDIT FACILITIES.DIPLOMAT PHARMACY - $800 MILLION FINANCING COMPRISED OF $250 MILLION REVOLVING CREDIT FACILITY, $150 MILLION TERM LOAN A FACILITY, $400 MILLION TERM LOAN B FACILITY.DIPLOMAT PHARMACY - PROCEEDS OF DEBT FINANCING WILL BE USED TO FINANCE LDI DEAL, REFINANCE DIPLOMAT'S CURRENT INDEBTEDNESS, AMONG OTHERS.  Full Article

Diplomat Pharmacy pulls forecast, delays results; shares hit record low

Diplomat Pharmacy Inc said on Friday it would withdraw its 2019 forecasts and delay its fourth-quarter and annual results as lower-than-expected performance in its pharmacy benefits management (PBM) business could result in a charge.